All partnering requests
See more requests
- Background
- What we're looking for
- What we can offer you
- Who we are
- Q&A
Have questions about this request?
Get them answered by the team at Bayer Pharma.
Background
Bayer’s Pharmaceuticals Research & Development division is working on potential future therapies for patients with cardiomyopathies of a genetic background for whom a therapy is currently not available.
We would like to use the stem cells to generate heart muscle cells and to investigate the differences of those cells in comparison to a healthy state to develop new therapeutic opportunities.
What we're looking for
We are seeking stem cells from patients with dilated cardiomyopathies (e.g. laminopathy or others). The genetic defect in those patients causing the disease should be known. Further, we would need certain clinical parameters of those patients. We would NOT use the cells themselves for clinical research & development.
Solutions of interest include:
- Induced pluripotent stem cells (iPSCs) from patients with dilated cardiomyopathies
Our must-have requirements are:
- The genetic defect in those patients causing the disease must be known
- The allowance by the donors to do research & development with the results of investigating those cells to develop human therapies.
- The allowance to use the induced pluripotent stem cells (iPSCs) to expand, reproduce, do gene sequencing, do expression analysis and further utilize
- You must be able to show us the detailed wording of the patient informed consent, if requested.
Our nice-to-have's are:
- Proven differentiation into cardiomyocytes
- Examined phenotype of cells
- Heart tissue from those patients instead of cells
What's out of scope:
- Embryonic stems cells
- Cells derived from animals
Acceptable technology readiness levels (TRL):
Levels 2-4
What we can offer you
Eligible partnership models:
Sponsored researchLicensingSupply/purchase
Benefits:
Sponsored Research
We are interested in follow-on research collaborations with relevant teams, including sponsored research or involvement of collaborators on a consultancy basis.Who we are
Bayer is a German multinational pharmaceutical and life sciences company with a more than 150-year history and core competencies in the areas of health care and agriculture.
Learn moreReviewers
GR
Gorden Redlich
Head of Strategic Outsourcing & Externalization
AN
Alberto Nobili
VP, Head of Co.Lab Cambridge
Q&A with Bayer Pharma
The Q&A is now closed.
Sort by:
Most upvoted
Q.
We develop hair loss treatments, which few based on stem cells (iPSC). While not sure if we align fully with your 'must-have requirements', we see potential collaboration. If interested will continue to the proposal stage
LS
March 7, 2024
2
A.
Dear Leegu Song, thanks for your message. If the must-have requirements are not met, then I think it not of interest for us. Best regards, Gorden
GR
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
March 7, 2024
Is this response helpful?
0
0
Q.
Would iPSC cardiomyopathy models generated with the help of non-for profit iPSC lines (HipSci) fall into the remit of the call?
Thanks K
1
A.
No, Katja. Sorry for that. Best regards, Gorden
GR
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
April 18, 2024
Is this response helpful?
0
0
Q.
What is the timeline you are looking for - we have a patient registry, some sequencing of HCM heart tissue, and an iPSC biobank but have yet to consent patients for iPSC donation.
1
A.
Dear Jeremy, we would like to start immediately, if possible. Best regards, Gorden
GR
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
May 6, 2024
Is this response helpful?
0
0
Q.
I am Professor Ofer Binah, Technion, Israel. I have iPSCs and iPSC-CMs from DCM laminopathy and DMD patients (papers published). Please inform the next step for initiating a collaboration with Bayer Pharma.
1
A.
Dear Ofer Binah, please submit your proposal on the platform. Then we have it in the pipeline for our review. Thanks. Gorden
GR
Gorden Redlich, Head of Strategic Outsourcing & Externalization, Bayer Pharma
May 21, 2024
Is this response helpful?
0
0
Sign up to access the full partnering request.
View the details of this request and connect directly with corporate R&D teams at Fortune 500 companies.Already have an account? Sign in
Share partnering request
2
finalists selectedRefine recommendations
Is this request relevant to you?
Eligible partners
Academic researchersStartups
Seeking partners focused on
BiochemistryBiopharmaceuticsBiophysicsCardiovascularCell BiologyClinical PharmacologyComplex SystemsDevelopmental BiologyGeneticsGenomics
7 more
Other recommended requests
NEW
Showcase solutions to industry
Don’t see a matching request for your technology, product, or service? List it and reach thousands of R&D decision-makers.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.